Related Experiment Videos
Severe alloimmune hemolytic anemia after renal transplantation
Ali Riza Odabaş1, Kutlay Naci Tutucu, Aydin Turkmen
1Department of Internal Medicine and Division of Nephrology, University of Istanbul, Istanbul Faculty of Medicine, Istanbul, Turkey. alirizao@yahoo.com
Nephron
|October 10, 2002
Summary
Severe alloimmune hemolytic anemia, a rare transplant complication, occurred in a renal transplant patient. This case highlights a potential risk associated with tacrolimus, differing from the commonly implicated cyclosporine.
Area of Science:
- Nephrology
- Immunology
- Transplantation
Background:
- Alloimmune hemolytic anemia (AHA) is a rare but serious complication after organ transplantation.
- Cyclosporine therapy has been historically linked to the majority of AHA cases.
- Understanding risk factors beyond cyclosporine is crucial for patient safety.
Observation:
- A patient undergoing renal transplantation developed severe AHA.
- The patient was treated with tacrolimus, an alternative immunosuppressant.
- The AHA was attributed to ABO minor incompatibility.
Findings:
- This case demonstrates tacrolimus-associated AHA in the context of ABO minor incompatibility.
- It challenges the assumption that cyclosporine is the sole drug implicated in transplant-related AHA.
- The findings underscore the importance of considering specific immunosuppressive agents in the etiology of AHA.
Implications:
- Clinicians should be vigilant for AHA even in patients treated with tacrolimus.
- Further research is needed to elucidate the mechanisms of tacrolimus-induced AHA.
- This case may inform revised monitoring protocols and risk assessments in renal transplant recipients.